Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Missouri meth bills

This article was originally published in The Tan Sheet

Executive Summary

Retail display of single-ingredient OTCs containing ephedrine, pseudoephedrine, or phenylpropanolamine would be limited to behind the counter or within six feet of a checkout register in stores without anti-theft systems under Missouri House Bill 470. Bill passed state assembly April 8, was referred to Senate Judiciary Committee, where an April 23 hearing is scheduled. Intended to limit availability of methamphetamine ingredients, bill also would block sales of more than six grams, or two packages, of any of the products. Senate Bill 442, also awaiting a hearing, includes ban on more than six grams of products and might incorporate other elements of HB 470. In testimony before Missouri Senate, CHPA has claimed bill will unduly restrict retailers without significant impact on crime, association says...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel